Minocycline: An Old Drug for a New Bug: Multidrug-Resistant Acinetobacter baumannii
Clinical Infectious Diseases December 1, 2014 V.59 suppl 6 S365-S366
Debra A. Goff1 and Keith S. Kaye2,3
1Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus
2Department of Medicine, Division of Infectious Diseases, Detroit Medical Center
3Wayne State University School of Medicine, Detroit, Michigan
Correspondence: Debra A. Goff, PharmD, FCCP, The Ohio State University Wexner Medical Center, Department of Pharmacy, 410 W 10th Ave, Rm 368 Doan Hall, Columbus, OH 43210 (firstname.lastname@example.org).
Acinetobacter baumannii is listed in the Centers for Disease Control and Prevention’s (CDC) report “Antibiotic Resistance Threats in the United States, 2013” as 1 of 18 microorganisms whose threat level is “urgent,” “serious,” or “concerning” according to their current and projected health and economic impacts .
The A. baumannii threat level is ranked as “serious” and carries a warning that this organism requires prompt and sustained action by healthcare providers to ensure that this problem pathogen does not continue to become more resistant to antimicrobials and spread.
The CDC estimates that nearly 7000 of 12 000 (63%) healthcare-associated Acinetobacter infections are multidrug resistant (MDR), defined as resistance to ≥3 different classes of antimicrobials.
Hospitals around the world are witnessing the loss of antibiotics for the treatment of MDR A. baumannii (MDR-AB) infections .
The lack of clinically effective antimicrobials to treat A. baumannii infections has led clinicians to reevaluate other “older” agents for the treatment of MDR-AB…..